Intuitive Surgical Reports Strong 2025 Results but Faces High Valuation Risks
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ISRG?
Source: Fool
- Significant Revenue Growth: Intuitive Surgical reported a 19% year-over-year revenue increase in Q4 2025, reaching approximately $2.9 billion, while full-year revenue rose 21% to $10.1 billion, indicating strong demand and market acceptance for its robotic-assisted surgical systems.
- Surgical Volume Continues to Rise: The company experienced an approximately 18% year-over-year growth in global procedure volume in Q4, installing 532 da Vinci surgical systems during the quarter compared to 493 a year ago, pushing its global installed base to over 11,100 systems, further solidifying its market leadership.
- Decelerating Growth Outlook: Management expects da Vinci procedures to grow by 13% to 15% in 2026, a notable slowdown from the 18% growth achieved in 2025, reflecting a cautious market sentiment that could impact investor confidence moving forward.
- High Valuation Risks: With a market capitalization of about $175 billion and a price-to-earnings ratio of approximately 63, Intuitive Surgical's high valuation poses significant risks, especially as the company faces a deceleration in growth, which could pressure its stock price even if operational performance remains strong.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ISRG?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ISRG
Wall Street analysts forecast ISRG stock price to rise
20 Analyst Rating
16 Buy
4 Hold
0 Sell
Strong Buy
Current: 485.850
Low
575.00
Averages
637.32
High
740.00
Current: 485.850
Low
575.00
Averages
637.32
High
740.00
About ISRG
Intuitive Surgical, Inc. develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system. The Company specializes in invasive care and robotic-assisted surgery. Its technologies include the da Vinci surgical systems and the Ion endoluminal system. The da Vinci surgical system is designed to enable surgeons to perform a range of surgical procedures within its targeted general surgery, urologic, gynecologic, cardiothoracic, and head and neck specialties and consists of a surgeon's console or consoles, a patient-side cart, and a high-performance vision system. The Ion endoluminal system is a flexible, robotic-assisted, catheter-based platform for which the cleared indication is minimally invasive biopsies in the lung and consists of a system cart, a controller, a catheter, and a vision probe. Its Ion system extends its commercial offering beyond surgery into diagnostic and endoluminal procedures.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Intuitive Surgical Reports Strong 2025 Results but Faces High Valuation Risks
- Significant Revenue Growth: Intuitive Surgical reported a 19% year-over-year revenue increase in Q4 2025, reaching approximately $2.9 billion, while full-year revenue rose 21% to $10.1 billion, indicating strong demand and market acceptance for its robotic-assisted surgical systems.
- Surgical Volume Continues to Rise: The company experienced an approximately 18% year-over-year growth in global procedure volume in Q4, installing 532 da Vinci surgical systems during the quarter compared to 493 a year ago, pushing its global installed base to over 11,100 systems, further solidifying its market leadership.
- Decelerating Growth Outlook: Management expects da Vinci procedures to grow by 13% to 15% in 2026, a notable slowdown from the 18% growth achieved in 2025, reflecting a cautious market sentiment that could impact investor confidence moving forward.
- High Valuation Risks: With a market capitalization of about $175 billion and a price-to-earnings ratio of approximately 63, Intuitive Surgical's high valuation poses significant risks, especially as the company faces a deceleration in growth, which could pressure its stock price even if operational performance remains strong.
See More
Market Update: Oil Price Surge and Corporate Earnings
- Oil Price Volatility: U.S. crude prices surged 4% due to reports of cargo ship attacks off Iran's coast, putting pressure on stocks and indicating ongoing geopolitical risks affecting market sentiment as the S&P 500 is set for a slightly lower open.
- Oracle's Strong Earnings: Oracle's quarterly results exceeded expectations, leading to a stock price increase of over 9%, with smooth AI buildout and remaining performance obligations exceeding $500 billion, highlighting the company's robust market position and growth potential.
- Kohl's Price Target Cut: Goldman Sachs lowered its price target for Kohl's from $15 to $13 while maintaining a sell rating, citing mixed quarterly results and decelerating same-store sales, reflecting challenges in the retail sector.
- Nike Upgrade: Barclays upgraded Nike from hold to buy, raising the price target from $64 to $73, arguing that tariff risks have eased, and management's progress in inventory management and margin stabilization provides a solid foundation for investment.
See More
Latest Wall Street Rating Updates
- JPMorgan Upgrades Oracle: JPMorgan upgraded Oracle from neutral to overweight, citing a 55% drop in shares since mid-September that has de-risked valuation, while shifting investor expectations to a lower bar for FY30 targets and OpenAI ramp.
- Evercore Reiterates Netflix Outperform: Evercore ISI's survey indicates strengthening customer satisfaction and pricing power for Netflix, reinforcing its status as a high-quality asset in global streaming, supported by unmatched scale and localized content production.
- Barclays Double Upgrades Arthur J. Gallagher: Barclays upgraded Arthur J. Gallagher from underweight to overweight, viewing the insurance company as a “great” defensive play in the current market environment, highlighting its resilience amid economic uncertainty.
- Barclays Reiterates Tesla Equal Weight: Barclays noted Tesla's battery energy storage system sales are capacity constrained, but expansion supports robust growth ahead, with expectations for Tesla to maintain top global market share in 2025, showcasing significant potential in the storage market.
See More
Intuitive Surgical and DexCom: Future Prospects Analysis
- Challenges for Intuitive Surgical: Intuitive Surgical has faced tariffs and competition from Medtronic's new Hugo system, resulting in a 13% stock price decline over the past year; however, it is expected to benefit from the growing surgical demand due to an aging population over the next decade, maintaining its market leadership.
- Market Potential: By 2034, the U.S. population aged 65 and older is projected to exceed those aged 18 and under, which will drive demand for Intuitive Surgical's da Vinci system, allowing for revenue and earnings growth despite competitive pressures due to its high switching costs and innovative capabilities.
- DexCom's Market Opportunities: DexCom's leadership in the CGM market remains intact despite last year's minor product recalls, with potential to expand its market share by targeting over 9 million insured diabetes patients who are not currently using CGM technology.
- New Product Development: DexCom's new product Stelo has attracted over 500,000 users in the U.S., targeting the large market of over 40% of the population with prediabetes, indicating significant growth potential in the non-diabetic patient segment, which is expected to drive future company growth.
See More
Intuitive Surgical and DexCom's Growth Prospects Amid Challenges
- Growing Market Demand: Intuitive Surgical faces tariffs and competitive pressures in 2025, yet its leadership in the robotic-assisted surgery market and the aging population trend are expected to drive demand growth over the next decade, with projections indicating that by 2034, the U.S. population aged 65 and older will surpass those under 18, enhancing its market potential.
- Competitive Pressure Management: Despite Medtronic's Hugo system gaining competitive clearance in the U.S., Intuitive Surgical can leverage its high switching costs and innovative capabilities to mitigate tariff impacts, with its installed base of 11,106 da Vinci devices poised to generate significant revenue growth.
- DexCom's Market Opportunities: DexCom's continuous glucose monitoring devices have substantial market potential among diabetes patients, as last year's product recalls affected only a small number of users, with over 9 million patients in the U.S. having insurance coverage but not utilizing the technology, indicating strong growth prospects.
- Attractive New Products: The launch of DexCom's Stelo product, which received clearance in 2024 and attracted over 500,000 users, targets the over 40% of the U.S. population with prediabetes, further expanding its market share and expected to drive future growth for the company.
See More
Intuitive Surgical Acquires European Distribution Business
- Acquisition of European Business: Intuitive Surgical has completed the acquisition of distribution businesses from ab medica, Abex, and Excelencia Robótica, enabling direct operations in Italy, Spain, and Portugal, which is expected to enhance the company's competitiveness in the European market.
- Market Integration and Leadership: Following the acquisition, operations have been integrated into ISRG's European commercial organization, led by Senior Vice President Dirk Barten, aimed at improving customer responsiveness and market adaptability.
- Surgical System Growth: By the end of 2025, ISRG's installed base of da Vinci surgical systems in Italy, Spain, and Portugal will exceed 470 units, with the Ion platform recently launched in Italy and Spain, indicating ongoing growth potential in the European market.
- Optimistic Market Outlook: The European surgical robots market is projected to grow from $2.10 billion in 2024 to $5.21 billion by 2031, with a CAGR of 14%, and ISRG is well-positioned to benefit from this growth due to its strong market presence.
See More
Intuitive Surgical Reports Strong 2025 Results but Faces High Valuation Risks
- Significant Revenue Growth: Intuitive Surgical reported a 19% year-over-year revenue increase in Q4 2025, reaching approximately $2.9 billion, while full-year revenue rose 21% to $10.1 billion, indicating strong demand and market acceptance for its robotic-assisted surgical systems.
- Surgical Volume Continues to Rise: The company experienced an approximately 18% year-over-year growth in global procedure volume in Q4, installing 532 da Vinci surgical systems during the quarter compared to 493 a year ago, pushing its global installed base to over 11,100 systems, further solidifying its market leadership.
- Decelerating Growth Outlook: Management expects da Vinci procedures to grow by 13% to 15% in 2026, a notable slowdown from the 18% growth achieved in 2025, reflecting a cautious market sentiment that could impact investor confidence moving forward.
- High Valuation Risks: With a market capitalization of about $175 billion and a price-to-earnings ratio of approximately 63, Intuitive Surgical's high valuation poses significant risks, especially as the company faces a deceleration in growth, which could pressure its stock price even if operational performance remains strong.
See More
Market Update: Oil Price Surge and Corporate Earnings
- Oil Price Volatility: U.S. crude prices surged 4% due to reports of cargo ship attacks off Iran's coast, putting pressure on stocks and indicating ongoing geopolitical risks affecting market sentiment as the S&P 500 is set for a slightly lower open.
- Oracle's Strong Earnings: Oracle's quarterly results exceeded expectations, leading to a stock price increase of over 9%, with smooth AI buildout and remaining performance obligations exceeding $500 billion, highlighting the company's robust market position and growth potential.
- Kohl's Price Target Cut: Goldman Sachs lowered its price target for Kohl's from $15 to $13 while maintaining a sell rating, citing mixed quarterly results and decelerating same-store sales, reflecting challenges in the retail sector.
- Nike Upgrade: Barclays upgraded Nike from hold to buy, raising the price target from $64 to $73, arguing that tariff risks have eased, and management's progress in inventory management and margin stabilization provides a solid foundation for investment.
See More
Latest Wall Street Rating Updates
- JPMorgan Upgrades Oracle: JPMorgan upgraded Oracle from neutral to overweight, citing a 55% drop in shares since mid-September that has de-risked valuation, while shifting investor expectations to a lower bar for FY30 targets and OpenAI ramp.
- Evercore Reiterates Netflix Outperform: Evercore ISI's survey indicates strengthening customer satisfaction and pricing power for Netflix, reinforcing its status as a high-quality asset in global streaming, supported by unmatched scale and localized content production.
- Barclays Double Upgrades Arthur J. Gallagher: Barclays upgraded Arthur J. Gallagher from underweight to overweight, viewing the insurance company as a “great” defensive play in the current market environment, highlighting its resilience amid economic uncertainty.
- Barclays Reiterates Tesla Equal Weight: Barclays noted Tesla's battery energy storage system sales are capacity constrained, but expansion supports robust growth ahead, with expectations for Tesla to maintain top global market share in 2025, showcasing significant potential in the storage market.
See More
Intuitive Surgical and DexCom: Future Prospects Analysis
- Challenges for Intuitive Surgical: Intuitive Surgical has faced tariffs and competition from Medtronic's new Hugo system, resulting in a 13% stock price decline over the past year; however, it is expected to benefit from the growing surgical demand due to an aging population over the next decade, maintaining its market leadership.
- Market Potential: By 2034, the U.S. population aged 65 and older is projected to exceed those aged 18 and under, which will drive demand for Intuitive Surgical's da Vinci system, allowing for revenue and earnings growth despite competitive pressures due to its high switching costs and innovative capabilities.
- DexCom's Market Opportunities: DexCom's leadership in the CGM market remains intact despite last year's minor product recalls, with potential to expand its market share by targeting over 9 million insured diabetes patients who are not currently using CGM technology.
- New Product Development: DexCom's new product Stelo has attracted over 500,000 users in the U.S., targeting the large market of over 40% of the population with prediabetes, indicating significant growth potential in the non-diabetic patient segment, which is expected to drive future company growth.
See More
Intuitive Surgical and DexCom's Growth Prospects Amid Challenges
- Growing Market Demand: Intuitive Surgical faces tariffs and competitive pressures in 2025, yet its leadership in the robotic-assisted surgery market and the aging population trend are expected to drive demand growth over the next decade, with projections indicating that by 2034, the U.S. population aged 65 and older will surpass those under 18, enhancing its market potential.
- Competitive Pressure Management: Despite Medtronic's Hugo system gaining competitive clearance in the U.S., Intuitive Surgical can leverage its high switching costs and innovative capabilities to mitigate tariff impacts, with its installed base of 11,106 da Vinci devices poised to generate significant revenue growth.
- DexCom's Market Opportunities: DexCom's continuous glucose monitoring devices have substantial market potential among diabetes patients, as last year's product recalls affected only a small number of users, with over 9 million patients in the U.S. having insurance coverage but not utilizing the technology, indicating strong growth prospects.
- Attractive New Products: The launch of DexCom's Stelo product, which received clearance in 2024 and attracted over 500,000 users, targets the over 40% of the U.S. population with prediabetes, further expanding its market share and expected to drive future growth for the company.
See More
Intuitive Surgical Acquires European Distribution Business
- Acquisition of European Business: Intuitive Surgical has completed the acquisition of distribution businesses from ab medica, Abex, and Excelencia Robótica, enabling direct operations in Italy, Spain, and Portugal, which is expected to enhance the company's competitiveness in the European market.
- Market Integration and Leadership: Following the acquisition, operations have been integrated into ISRG's European commercial organization, led by Senior Vice President Dirk Barten, aimed at improving customer responsiveness and market adaptability.
- Surgical System Growth: By the end of 2025, ISRG's installed base of da Vinci surgical systems in Italy, Spain, and Portugal will exceed 470 units, with the Ion platform recently launched in Italy and Spain, indicating ongoing growth potential in the European market.
- Optimistic Market Outlook: The European surgical robots market is projected to grow from $2.10 billion in 2024 to $5.21 billion by 2031, with a CAGR of 14%, and ISRG is well-positioned to benefit from this growth due to its strong market presence.
See More
